Atlas Capital Advisors Inc. Takes $1.87 Million Position in Abbott Laboratories $ABT

Atlas Capital Advisors Inc. bought a new position in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 14,913 shares of the healthcare product maker’s stock, valued at approximately $1,868,000.

Several other large investors also recently bought and sold shares of ABT. Norges Bank purchased a new stake in Abbott Laboratories during the 4th quarter worth approximately $2,938,892,000. Invesco Ltd. grew its position in Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ninety One UK Ltd purchased a new stake in Abbott Laboratories during the 4th quarter worth approximately $336,815,000. Vanguard Group Inc. grew its position in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Finally, Stifel Financial Corp grew its position in Abbott Laboratories by 122.0% during the 4th quarter. Stifel Financial Corp now owns 3,947,686 shares of the healthcare product maker’s stock worth $494,610,000 after purchasing an additional 2,169,184 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Evercore decreased their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Jefferies Financial Group decreased their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Argus decreased their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.38.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Stock Performance

ABT opened at $87.89 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a fifty day moving average price of $91.46 and a 200 day moving average price of $107.98. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The stock has a market cap of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the previous year, the business posted $1.09 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.